Aminolevulinic acid and Bumetanide Injection
Determining the interaction of Aminolevulinic acid and Bumetanide Injection and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Patients exposed to photosensitizing agents may be at increased risk of a phototoxic skin reaction (severe sunburn) during use of aminolevulinic acid. MANAGEMENT: Photosensitizing agents (e.g., fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, St. John's wort) and topical preparations containing aminolevulinic acid should generally not be administered for 24 hours before and after oral administration of aminolevulinic acid. Some authorities recommend avoiding exposure to any photosensitizing agent for up to 2 weeks after oral administration of aminolevulinic acid, if possible. Patients should also avoid exposure of the eyes and skin to sunlight or bright indoor lights (e.g., examination lamps, operating room lamps, tanning beds, lights at close proximity) for 48 hours after receiving aminolevulinic acid. References "Product Information. Gleolan (aminolevulinic acid)." NX Development Corp, Lexington, KY.
Professional:GENERALLY AVOID: Patients exposed to photosensitizing agents may be at increased risk of a phototoxic skin reaction (severe sunburn) during use of aminolevulinic acid.
MANAGEMENT: Photosensitizing agents (e.g., fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, St. John's wort) and topical preparations containing aminolevulinic acid should generally not be administered for 24 hours before and after oral administration of aminolevulinic acid. Some authorities recommend avoiding exposure to any photosensitizing agent for up to 2 weeks after oral administration of aminolevulinic acid, if possible. Patients should also avoid exposure of the eyes and skin to sunlight or bright indoor lights (e.g., examination lamps, operating room lamps, tanning beds, lights at close proximity) for 48 hours after receiving aminolevulinic acid.
- "Product Information. Gleolan (aminolevulinic acid)." NX Development Corp, Lexington, KY.
Generic Name: aminolevulinic acid
Brand name: Gleolan
Synonyms: n.a.
Generic Name: bumetanide
Brand name: Bumex
Synonyms: Bumetanide (oral/injection), Bumetanide
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Aminolevulinic acid-Bumetanide oral/injection
- Aminolevulinic acid-Bumetanide Tablets
- Aminolevulinic acid-Bumex
- Aminolevulinic acid-Bumex Injection
- Aminolevulinic acid-Bumex oral/injection
- Aminolevulinic acid-BumP DHA
- Bumetanide Injection-Aminolevulinic Acid (Systemic)
- Bumetanide Injection-Aminolevulinic Acid Gel
- Bumetanide Injection-Aminolevulinic Acid Hydrochloride
- Bumetanide Injection-Aminolevulinic Acid Solution
- Bumetanide Injection-Aminolevulinic acid topical
- Bumetanide Injection-Aminomine